Amino acid metabolism, lipid metabolism, and oxidative stress are associated with post-stroke depression: a metabonomics study

Abstract

Background Post-stroke depression (PSD) is a mood disorder characterized by depression and anhedonia caused by stroke. Metabolomics identified metabolites associated with PSD, but previous studies are based on gas chromatography (GC)/mass spectrometry (MS). This study aimed to perform a liquid chromatography (LC)-MS-based metabolomics study of the plasma metabolite profiles between patients with PSD and controls. Methods This was a prospective study of patients with stroke enrolled between July and December 2017 at the Second Affiliated Hospital of Nanchang University. Patients were grouped as Hamilton Depression Rating Scale > 7 (PSD) or < 7 (controls). Metabonomics profiling of plasma sampled was conducted by LC-MS. By combining multivariable and univariable statistical analyses, significant differential metabolites between the two groups were screened. The threshold for significant differences was VIP ≥1 and P < 0.05. Log2FC is the logarithm of the mean ratio between the two groups. Results There were no significant difference with respect to age, NIHSS score, and MMSE between the two groups (all P > 0.05). There were six differential metabolites between the PSD and stroke groups, of which three metabolites were increased and three were decreased. Compared with the control group, p-chlorophenylalanine (Log2FC = 1.37, P = 0.03), phenylacetyl glutamine (Log2FC = 0.21, P = 0.048), and DHA (Log2FC = 0.77, P = 0.01) levels were higher in the PSD group, while betaine (trimethylglycine) (Log2FC = − 0.79, P = 0.04), palmitic acid (Log2FC = − 0.51, P = 0.001), and MHPG-SO4 (Log2FC = − 2.37, P = 0.045) were decreased. Conclusion Plasma metabolomics showed that amino acid metabolism (phenylacetyl glutamine, p-chlorophenylalanine, trimethylglycine), lipid metabolism (DHA, palmitic acid, trimethylglycine), and oxidative stress (DHA, palmitic acid, trimethylglycine) were associated with PSD. These results could help to reveal the pathophysiological mechanism of PSD and eventually identify treatment targets.

Hemispheric Difference of Regional Brain Function Exists in Patients With Acute Stroke in Different Cerebral Hemispheres: A Resting-State fMRI Study

“…As one of the cerebral diseases in the "brain program, " stroke is listed as the primary cause of disability and death (Wang et al, 2013(Wang et al, , 2017 due to its characteristics of high incidence, high disability rate, and high mortality rate. The existing basic researches mainly concentrate on proteomics, genomics, and metabolomics (Nguyen et al, 2016;Hasin et al, 2017;Wang et al, 2020). Neuroimaging technology is a research focus in the field of in vivo research on post-stroke injury.…”

Metabolomics Analysis on Mice With Depression Ameliorated by Acupoint Catgut Embedding

“…In agreement with previous works, we found that the amount of glycerin was remarkably increased in depression mice. In contrast, ACE effectively reduced the glycerin level (61,62). Spermidine could promote autophagic activation, which may induce neuronal damage in the hippocampus (61,62).…”

“…In contrast, ACE effectively reduced the glycerin level (61,62). Spermidine could promote autophagic activation, which may induce neuronal damage in the hippocampus (61,62). ACE administration effectively suppressed the level of spermidine FIGURE 5 | Differential metabolites expression in the brain of mice between the CON, CORT, and ACE groups.…”

Depressed Mood after Stroke: Predictive Factors at Six Months Follow-Up

“…Persons with PSD have higher mortality rates [ 7 , 10 ], more pronounced cognitive deficits, more long-term disability, lower quality of life and higher rates of suicidal ideation as compared to post-stroke patients without depression, indicating that early detection and treating depression are important after a stroke [ 11 , 12 , 13 , 14 ]. Thus, the consequences of not detecting depression symptoms at an early stage can be relevant for the patient as well as health systems [ 12 , 15 , 16 ].…”